International randomised controlled trial evaluating metabolic syndrome in type 2 diabetic cigarette smokers following switching to combustion-free nicotine delivery systems: the DIASMOKE protocol. Issue 4 (27th April 2021)

• Record Type: Journal Article
• Authors: Krysinski, Arkadiusz; Russo, Cristina; John, Sarah; Belsey, Jonathan D; Campagna, Davide; Caponnetto, Pasquale; Vudu, Lorina; Lim, Chong Wei; Purrello, Francesco; Di Mauro, Maurizio; Iqbal, Farrukh; Fluck, David; Franek, Edward; Polosa, Riccardo; Sharma, Pankaj
• Is Part Of: BMJ open. Volume 11:Issue 4(2021)
• Publication Date: 2021-04-27
• Subjects: diabetes & endocrinology -- lipid disorders -- hypertension -- general diabetes; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2020-045396
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Introduction: Reducing exposure to cigarette smoke is an imperative for public health and for patients with diabetes. Increasingly, combustion-free nicotine delivery systems (C-F NDS) such as e-cigarettes and heated tobacco products are substituting conventional cigarettes and accelerating the downward trends in smoking prevalence. However, there is limited information about the long-term health impact in patients with diabetes who use C-F NDS. This randomised trial of type 2 diabetic cigarette smokers will test the hypothesis that following a switch from conventional cigarettes to C-F NDS a measurable improvement in metabolic syndrome (MetS) factors will be shown over the course of 2 years. Methods and analysis: The study is multicentre and thus will take place in five locations in four countries in an ambulatory setting. A total of 576 patients with diabetes will be randomised (1:2 ratio) to either a control arm (Study Arm A), in which they will be offered referral to smoking cessation programmes or to an intervention arm (Study Arm B) assigned to C-F NDS use. Participants will be at least 23 years old and of any gender. Patient recruitment will start in February 2021 and is expected to be completed by December 2021. Primary outcome measures include fasting plasma glucose, blood pressure, triglycerides, high-density lipoprotein and waist circumference, while secondary feature absolute change in the sum of the individual factors of MetS and change in each individual factor of MetS measured at each study time point. Ethics and dissemination: The approval of research ethics committee (REC) regarding the trial protocol, informed consent forms and other relevant documents is required to commence the study. Substantial amendments to the study protocol cannot be implemented until the REC grants a favourable opinion. The results of the study are intended to be published as articles in high quality peer-reviewed journals and disseminated through conference papers. Trial registration number: NCT04231838 . Pre-results stage.